POCI — what changed in the latest 10-K
A section-by-section comparison of POCI's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-K · 2026-09-28 vs the prior 10-K · 2025-09-29
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| Business | Text added/removed | +5 | −3 | ~10 | 17 |
| Risk factors | Text added/removed | +1 | −1 | ~10 | 89 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| MD&A | Text added/removed | +17 | −17 | ~3 | 3 |
| Market risk (Item 7A) | No paragraph-level changes | 0 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
Business
Text added vs the prior filing · source: 10-K · 2026-09-28
The technology developed to support the design, fabrication and manufacturing of Microprecision™ lenses and associated assemblies is also used to satisfy the needs of defense and aerospace systems that require small size and weight, particularly those required for satellite network communications, w…
We believe satellite optical communications represents a significant market opportunity for our advanced defense and aerospace capabilities. Optical Communication Terminals used in emerging satellite constellations require compact, lightweight and high-performance optical assemblies, creating a stro…
During the fiscal year ending June 30, 2026, we sold products and services to 266 customers with one customer accounting for approximately 41% of total revenues and another customer accounting for 27% of our total revenues. The loss of these customers would have a material impact on our business. Fo…
Two customer accounts receivable balances accounted for 34.4% and 22.8% of total receivables on June 30, 2026. Two customer accounts receivable balances accounted for 32.1% and 17.9% of total receivables on June 30, 2025.
Foreign Requirements. All our medical products are manufactured in conformity with ISO 13485:2016, using a comprehensive Quality Management System (QMS) that helps meet both international and EU regulatory standards. Our failure to comply with ISO 13485 or other applicable regulatory requirements wo…
Text removed vs the prior filing · source: 10-K · 2025-09-29
During the fiscal year ending June 30, 2025, we sold products and services to 278 customers with one customer accounting for approximately 22% of total revenues and another customer accounting for 20% of our total revenues. The loss of these customers would have a material impact on our business. Fo…
Two customer accounts receivable balances accounted for 32.1% and 17.9% of total receivables on June 30, 2025. Two customer accounts receivable balances accounted for 15.4% and 12.1% of total receivables on June 30, 2024.
Foreign Requirements. All our medical products are manufactured in conformity with ISO 13485:2016, using a comprehensive Quality Management System (QMS) that helps meet both international and EU regulatory standards. ISO 13485 is an internationally recognized standard that emphasizes risk management…
Risk factors
Text added vs the prior filing · source: 10-K · 2026-09-28
During the fiscal year ending June 30, 2026, one customer accounted for approximately 41% of total revenues and another customer accounted for 27% of our total revenues, representing a significant increase in customer concentration compared to prior years. For the fiscal year ended June 30, 2025, on…
Text removed vs the prior filing · source: 10-K · 2025-09-29
A small number of customers may continue to represent a significant portion of our total revenues in any given period. These customers may not consistently purchase our products at a particular rate over any subsequent period. A loss of any of these customers could adversely affect our revenues.
MD&A
Text added vs the prior filing · source: 10-K · 2026-09-28
In February 2026, the Supreme Court of the United States determined that certain tariffs imposed pursuant to the International Emergency Economic Powers Act (“IEEPA”) were not authorized by law. Subsequent rulings by the U.S. Court of International Trade have directed the U.S. Customs and Border Pro…
Accordingly, during the year ended June 30, 2026, the Company recorded a receivable of $880,598 within accounts receivable in the balance sheet, representing recovery of IEEPA tariffs previously paid, with a corresponding offset to cost of goods sold. In addition, the Company recorded a $558,266 lia…
Results of Operations for the Fiscal Year Ended June 30, 2026 as Compared to the Fiscal Year Ended June 30, 2025
Revenue from Engineering Design Services decreased 29.7% during the year ending June 30, 2026 from the prior year ending June 30, 2025. Revenue decreases in the engineering category resulted from decreased demand for services, primarily from the transfer of our single-use cystoscope program from dev…
Revenue from Systems Manufacturing increased 172.9% during the year ending June 30, 2026 from the prior year ending June 30, 2025. Revenue increases in this category resulted from significant increases in customer demand and the resultant scaling of manufacturing capabilities.
Text removed vs the prior filing · source: 10-K · 2025-09-29
Results of Operations for the Fiscal Year Ended June 30, 2025 as Compared to the Fiscal Year Ended June 30, 2024
Revenue from Engineering Design Services decreased 42.0% during the year ending June 30, 2025 from the prior year ending June 30, 2024. Revenue decreases in the engineering category resulted from decreased demand for services, primarily from the transfer of our single-use cystoscope program from dev…
Revenue from Systems Manufacturing increased 122.2% during the year ending June 30, 2025 from the prior year ending June 30, 2024. Revenue increases in this category resulted from increased demand for manufacturing services as design services engagements concluded and progressed to manufacturing.
Revenue from the MicroOptics Lab decreased 21.5% during the year ending June 30, 2025 from the prior year ending June 30, 2024, primarily due to reorder timing.
Revenue from Ross Optical Industries decreased 9.8% for the year ending June 30, 2025 from the prior year ending June 30, 2024. We believe the decrease continues to be attributable to a general, industry-wide slowdown, coupled with uncertainty driven by evolving tariff costs, which has led customers…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice